Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709274 | 0.94 | SLC6A3 (0.33) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Hydrochloric Acid SCHEMBL27916528 | 0.93 | SLC6A2 (0.33) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL27650831 | 0.93 | SLC6A2 (0.33) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL28267413 | 0.78 | SLC6A3 (0.34) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4461978 | 0.76 | SLC6A3 (0.43) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Tert-Butyl Formate SCHEMBL27801680 | 0.76 | TDP1 (0.38) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL27952382 | 0.75 | — | — | |
| SCHEMBL6050426 | 0.75 | SLC6A3 (0.42) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL271159 | 0.75 | SLC6A3 (0.42) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL5535061 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1221440-B1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | OTSUKA PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-6642223-B2 | A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-0765314-B1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMA CO LTD (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1221440-A1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | Otsuka Pharmaceutical Company, Limited (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-20020049194-A1 | Benzoheterocyclic derivatives | OGAWA HIDENORI (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6335327-B1 | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6096735-A | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049194-A1 | Benzoheterocyclic derivatives | AVPR2, AVPR1A, AVPR1B | SLC6A3 711/4885SLC6A2 1402/4885SLC6A4 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.